Your Medication Isn't Working. Your Genes May Be Why.

CYP2D6 is an enzyme powerhouse. Your liver uses it to break down roughly 25% of all prescription drugs on the market. That includes almost every common antidepressant, pain reliever, heart medication, and antipsychotic. When this enzyme works normally, it metabolizes these drugs at a predictable rate, clearing them from your body on schedule.

Here’s the problem: roughly 7 to 10% of people of European ancestry have a version of CYP2D6 that works poorly, or they carry extra copies that work too fast. Poor metabolizers accumulate these drugs in their bloodstream. A standard dose becomes a double dose, then triple, and your body can’t clear it fast enough. Ultra-rapid metabolizers, on the other hand, burn through medication so quickly that the standard dose never reaches a therapeutic level.

If you’re a poor metabolizer and you take an antidepressant, you might experience severe side effects at a dose that should be mild. If you’re ultra-rapid and you take an opioid, you’ll get little to no pain relief and be labeled “drug-seeking” by your doctor. If you metabolize codeine slowly, it converts to morphine too efficiently and becomes dangerous. Your doctor has no way to know this is happening without a genetic test.

CYP2C19 is responsible for activating a blood thinner called clopidogrel (Plavix), one of the most commonly prescribed medications after heart stents or strokes. This enzyme also breaks down many antidepressants, PPIs, and other psychiatric drugs. The enzyme is vital because clopidogrel is what’s called a prodrug, meaning your body has to convert it into its active form before it can work.

Roughly 2 to 15% of people (depending on ancestry) carry a variant that makes CYP2C19 work poorly or not at all. If you’re a poor metabolizer of CYP2C19, clopidogrel remains inactive in your blood, and you get zero antiplatelet protection. You’re left thinking your blood thinner is working when it’s doing nothing. Conversely, ultra-rapid metabolizers convert clopidogrel too quickly, leading to excessive bleeding risk. For antidepressants, poor metabolizers accumulate the drug and experience side effects; ultra-rapid metabolizers find it ineffective.

You might be prescribed clopidogrel after a cardiac event and have a second heart attack a few months later, all because your genes made that prodrug inert. Your doctor won’t suspect pharmacogenomics. They’ll think you’re unlucky, or the clot was resistant. Meanwhile, a genetic test would have flagged you for a different antiplatelet drug entirely.

CYP2C9 breaks down warfarin, the most widely prescribed oral blood thinner for atrial fibrillation and other clotting disorders. It also metabolizes NSAIDs like ibuprofen and naproxen, as well as many statin cholesterol drugs. This enzyme’s job is straightforward, but the stakes are high because warfarin has a narrow therapeutic window: too little and you clot; too much and you bleed.

Approximately 5 to 10% of people of European ancestry carry variants that slow CYP2C9. If you’re a poor metabolizer, warfarin accumulates in your blood faster than your body can clear it, and standard doses can cause serious or life-threatening bleeding. Your doctor may have no idea why you’re bruising easily or having nosebleeds if they haven’t tested your genes. Even worse, you might be labeled as noncompliant when really your genetics are making the standard dose too high for your body.

You go to the ER with unexplained bleeding. You’ve been on a standard warfarin dose for months with a genetic predisposition to accumulate it. Your INR (clotting measure) suddenly spikes. A genetic test would have predicted this from day one and guided your doctor to a lower dose from the start. Instead, you’re treated as an emergency.

VKORC1 is an enzyme that recycles vitamin K in your body. Warfarin works by blocking VKORC1, which disrupts the clotting cascade and thins your blood. But here’s the critical detail: people with different VKORC1 variants have dramatically different sensitivity to warfarin’s effect. Some people’s VKORC1 is extremely sensitive to warfarin blocking; others are resistant.

Roughly 40% of people of European ancestry carry the A allele at position 1639 in VKORC1, which causes reduced vitamin K recycling. If you carry this variant, your body is exquisitely sensitive to warfarin, and you require much lower doses than the population average to achieve the same anticoagulation effect. If you’re given a standard dose based on population assumptions, your blood will thin too much and you’ll bleed. Meanwhile, someone without this variant might tolerate the same dose safely.

You start warfarin for a new diagnosis of atrial fibrillation. Your doctor prescribes the standard starting dose. Within a week you’re bruising, and your INR is dangerously high. You’re hospitalized, given vitamin K to reverse the effect, and told to take less warfarin next time. But your genes predicted this outcome from the moment you filled the prescription. A genetic test before starting warfarin would have guided your doctor to a lower starting dose, and you would have never had a bleeding crisis.

SLCO1B1 is a transporter protein that pulls statins from your bloodstream into your liver, where they do their job of lowering cholesterol. If this transporter works efficiently, statins get into your liver quickly and the dose you swallow reaches its intended target. If the transporter works poorly, statins stay in your bloodstream longer and your muscles are exposed to higher concentrations.

Roughly 15% of people carry the *5 variant (rs4149056) that reduces SLCO1B1 function. If you carry this variant and take a statin, especially simvastatin, your muscles are bathed in higher drug concentrations than intended, dramatically increasing your risk of muscle pain and breakdown (statin myopathy). You experience joint and muscle aches that seem to worsen over weeks. Your doctor blames your age or exercise routine. You stop exercising to avoid pain. Your cholesterol creeps back up. You’re labeled as intolerant to statins when really your genetics made that particular drug the wrong choice for you.

You’re prescribed simvastatin for high cholesterol. After three weeks, your legs ache. After six weeks, you can barely walk. Your doctor dismisses it as coincidence or normal aging. You stop the medication. A genetic test would have identified your SLCO1B1 variant and recommended a different statin (like pravastatin or rosuvastatin) that doesn’t rely on this transporter, or a much lower simvastatin dose.

MTHFR is an enzyme that converts folate into its active form, which your body uses for methylation reactions, DNA synthesis, and countless metabolic processes. Many medications depend on adequate folate metabolism to work properly. Methotrexate, a drug used for rheumatoid arthritis, psoriasis, and cancer, works by disrupting folate-dependent pathways. Your response to methotrexate depends partly on how efficiently your MTHFR enzyme functions.

Approximately 40% of people of European ancestry carry the C677T variant that reduces MTHFR enzyme activity by 30 to 70%. If you carry this variant and take methotrexate, your body’s disrupted folate metabolism compounds with the drug’s folate-blocking action, leaving you with inadequate methylation and nucleotide synthesis for normal cell function. You might experience more severe side effects like nausea, mouth sores, and bone marrow suppression at doses that others tolerate well. Or the drug might be less effective because your baseline folate metabolism is already compromised.

You start methotrexate for rheumatoid arthritis. You experience severe nausea and mouth ulcers at a dose that your rheumatologist says should be tolerable. You’re switched to a lower dose, which doesn’t work well for your arthritis. You end up struggling with both side effects and inadequate disease control. A genetic test would have shown your MTHFR variant and guided your doctor to add methylated folate supplementation from the start, or choose a different disease-modifying drug altogether.